Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 3/20 | 0.50 |
| ▸ | MAOB | P27338 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6866612 | 0.80 | MAOA (0.57) | SMN1; SMN2MAOAMAOBALDH1A1KDM4E | |
| SCHEMBL6866606 | 0.80 | MAOA (0.57) | SMN1; SMN2MAOAMAOBALDH1A1KDM4E | |
| SCHEMBL13373201 | 0.78 | MAOA (0.50) | SMN1; SMN2MAOAMAOBALDH1A1KDM4E | |
| SCHEMBL22702081 | 0.77 | SMN1; SMN2 (0.49) | SMN1; SMN2MAOAMAOBALDH1A1KDM4E | |
| SCHEMBL26780011 | 0.77 | MAOA (0.53) | SMN1; SMN2MAOAMAOBALDH1A1KDM4E | |
| SCHEMBL399162 | 0.77 | SMN1; SMN2 (0.56) | SMN1; SMN2MAOAMAOBALDH1A1KDM4E | |
| SCHEMBL14465565 | 0.77 | MAOA (0.53) | SMN1; SMN2MAOAMAOBALDH1A1KDM4E | |
| SCHEMBL12614725 | 0.77 | MAOA (0.53) | SMN1; SMN2MAOAMAOBALDH1A1KDM4E | |
| Bromide SCHEMBL9508770 | 0.76 | MAOA (0.52) | SMN1; SMN2MAOAMAOBALDH1A1KDM4E | |
| SCHEMBL18871477 | 0.75 | SMN1; SMN2 (0.54) | SMN1; SMN2ALDH1A1KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111182898-B | Methods for treating huntington's disease | PTC医疗公司 | 2024-04-16 | — | — | CN | disclosed |
| US-20240067646-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. | 2024-02-29 | — | — | US | disclosed |
| US-20230310651-A1 | METHODS FOR MODULATING RNA SPLICING | PTC THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | US | disclosed |
| EP-4249472-A2 | METHODS FOR MODULATING RNA SPLICING | PTC Therapeutics, Inc. (US) | 2023-09-27 | — | — | EP | disclosed |
| US-11753407-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230272367-A1 | METHODS FOR MODULATING RNA SPLICING | PTC THERAPEUTICS, INC. (US) | 2023-08-31 | — | — | US | disclosed |
| EP-3644996-B1 | METHODS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2023-07-26 | — | — | EP | disclosed |
| US-11702646-B2 | Methods for modulating RNA splicing | PTC THERAPEUTICS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| EP-3310169-B1 | METHODS FOR MODULATING RNA SPLICING | PTC THERAPEUTICS INC (US) | 2023-05-17 | — | — | EP | disclosed |
| US-11602567-B2 | Methods for modulating RNA splicing | PTC THERAPEUTICS, INC. (US) | 2023-03-14 | — | — | US | disclosed |
| EP-2819519-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC Therapeutics, Inc. (US) | 2015-01-07 | — | — | EP | disclosed |
| US-20150005289-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. | 2015-01-01 | — | — | US | disclosed |
| EP-2812004-A2 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC Therapeutics, Inc. (US) | 2014-12-17 | — | — | EP | disclosed |
| EP-2809322-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC Therapeutics, Inc. (US) | 2014-12-10 | — | — | EP | disclosed |
| EP-2797592-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC Therapeutics, Inc. (US) | 2014-11-05 | — | — | EP | disclosed |
| WO-2013142236-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2013-09-26 | — | — | WO | disclosed |
| WO-2013130689-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2013-09-06 | — | — | WO | disclosed |
| WO-2013119916-A2 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2013-08-15 | — | — | WO | disclosed |
| WO-2013112788-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2013-08-01 | — | — | WO | disclosed |
| WO-2013101974-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2013-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067646-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, GYS1 | SMN1; SMN2 1/4885MAOA 1254/4885MAOB 512/4885 |
| US-20150005289-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, GYS1 | SMN1; SMN2 1/4885MAOA 1697/4885MAOB 1000/4885 |
| US-20230272367-A1 | METHODS FOR MODULATING RNA SPLICING | RBM17, SNRPE, HNRNPM | SMN1; SMN2 1148/4885MAOA 3552/4885MAOB 3342/4885 |
| US-11702646-B2 | Methods for modulating RNA splicing | RBM17, SNRPE, HNRNPM | SMN1; SMN2 1148/4885MAOA 3552/4885MAOB 3342/4885 |
| US-11602567-B2 | Methods for modulating RNA splicing | RBM17, SNRPE, RBM3 | SMN1; SMN2 766/4885MAOA 3215/4885MAOB 2999/4885 |
| US-20230310651-A1 | METHODS FOR MODULATING RNA SPLICING | RBM17, SNRPE, RBM3 | SMN1; SMN2 766/4885MAOA 3215/4885MAOB 2999/4885 |
| US-11753407-B2 | Compounds for treating spinal muscular atrophy | SMN1; SMN2, CPT1B, GYS1 | SMN1; SMN2 1/4885MAOA 1287/4885MAOB 624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.